A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

ClinicalTrials.gov ID: NCT06051409

Public ClinicalTrials.gov record NCT06051409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL

Study identification

NCT ID: NCT06051409
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Enrollment: 350 participants

Conditions and interventions

Conditions

Interventions

Investigator's choice of TKI Drug
Olverembatinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 30, 2023
Primary completion: Dec 30, 2027
Completion: Jun 29, 2029
Last update posted: Apr 29, 2026

2023 – 2029

United States locations

U.S. sites: 16
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
Ascentage Investigative Site #1044	Birmingham	Alabama	35233	Not yet recruiting
Ascentage Investigative Site #1062	Duarte	California	91010	Not yet recruiting
Ascentage Investigative Site #1134	Los Angeles	California	90048	Not yet recruiting
Ascentage Investigative Site #1059	Los Angeles	California	90095	Not yet recruiting
Ascentage Investigative Site #1142	Miami	Florida	33155	Not yet recruiting
Ascentage Investigative Site #1045	Augusta	Georgia	30912	Not yet recruiting
Ascentage Investigative Site #1158	Indianapolis	Indiana	46202	Not yet recruiting
Ascentage Investigative Site #1069	Indianapolis	Indiana	46237	Not yet recruiting
Ascentage Investigative Site #1084	Lexington	Kentucky	40536	Not yet recruiting
Ascentage Investigative Site #1064	Hackensack	New Jersey	07601	Not yet recruiting
Ascentage Investigative Site #1098	New Brunswick	New Jersey	08901	Not yet recruiting
Ascentage Investigative Site #1160	Stony Brook	New York	11794	Not yet recruiting
Ascentage Investigative Site #1151	The Bronx	New York	10461	Not yet recruiting
Ascentage Investigative Site #1501	Houston	Texas	77030	Not yet recruiting
Ascentage Investigative Site #1806	Seattle	Washington	98104	Not yet recruiting
Ascentage Investigative Site #1155	Morgantown	West Virginia	26506	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06051409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 29, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06051409 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →